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Self-assemblingNon-viral vector formulations comprise typically complexes of nucleic acids with cationic polymers or lipids.
However, for in vivo applications cationic formulations suffer from problems of poor tissue penetration, non-
speciﬁc binding to cells, interaction with serum proteins and cell adhesion molecules and can lead to inﬂamma-
tory responses. Anionic formulationsmay provide a solution to these problems but they have not beendeveloped
to the same extent as cationic formulations due to difﬁculties of nucleic acid packaging and poor transfection
efﬁciency. We have developed novel PEGylated, anionic nanocomplexes containing cationic targeting peptides
that act as a bridge between PEGylated anionic liposomes and plasmid DNA. At optimized ratios, the components
self-assemble into anionic nanocomplexes with a high packaging efﬁciency of plasmid DNA. Anionic PEGylated
nanocomplexes were resistant to aggregation in serum and transfected cells with a far higher degree of
receptor-targeted speciﬁcity than their homologous non-PEGylated anionic and cationic counterparts.
Gadolinium-labeled, anionic nanoparticles, administered directly to the brain by convection-enhanced delivery
displayed improved tissue penetration and dispersal as well as more widespread cellular transfection than
cationic formulations. Anionic PEGylated nanocomplexes have widespread potential for in vivo gene therapy
due to their targeted transfection efﬁciency and ability to penetrate tissues.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license. 1. Introduction
There is great interest in developing nanocomplex formulations for
gene delivery in vivo and for therapeutic applications as alternatives to
viral vectors, due to their ability to package a wide range of nucleic
acids, their low immunogenicity which allows repeated administration
and their potential for chemical modiﬁcation of vector components to
optimize performance [1,2]. Non-viral vectors for gene or siRNAdelivery
usually comprise formulations of cationic polymers or liposomes that
self-assemble electrostatically onmixingwith nucleic acids at optimized
ratios to form cationic nanocomplexes that are often very effective as
in vitro transfection agents [3–6] but often display poor transfection ef-
ﬁciency in vivo due to their aggregation in serum and to non-speciﬁc,
charge-mediated binding to anionic cell surfaces and extracellular
adhesion molecules [7–9]. Stealth coatings, of nanocomplexes, for44 2079052810.
.Open access under CC BY license. example by PEGylation, can enhance serum stability and minimize non-
speciﬁc interactions but usually reduce transfection efﬁciencies [10,11].
An alternative approach is to formulate anionic nanocomplexes that
offer the advantages of better targeting speciﬁcity, lower cytotoxicity
and less interactionwith serum components when compared to cation-
ic formulations [12–14]. However, the use of anionic nanocomplexes
has proven problematic due to the inherent problem of achieving self-
assembly with anionic vector components and nucleic acids of the
same charge [15]. Anionic nanocomplexes also display poor transfection
efﬁciency due to charge repulsion at the anionic cell surface and conse-
quently poor cell binding and uptake. Strategies developed to overcome
these challenges include using cationic agents such as Ca2+ cations
[14,16–19] or protamine [20–22] to act as an electrostatic bridge be-
tween anionic lipids and nucleic acids, the use of anionic reagents
such as polyglutamate to coat cationic nanoparticles with an anionic
shell [23,24] or by formulating nanoparticles with pH-tunable lipids
[25]. These anionic formulations and strategies have all shown promise
for in vitro and in vivo delivery of DNA and siRNA indicating their poten-
tial for non-viral genetic therapies.
We have previously described a cationic receptor-targeted
nanocomplex (RTN), comprising a mixture of cationic liposomes (L), a
sixteen lysine peptide with a cyclic seven amino acid targeting domain
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delivery in the airway epithelium [26,27], tumors [28–30] and vascular
tissues [31,32]. Furthermore, we recently have described anionic
nanocomplexes that comprised a peptide with a neurotensin receptor-
targeting motif and an anionic liposome (1:1 formulation of DOPG:
DOPE) which showed targeted transfection in vitro and displayed much
better distribution in rat brain than homologous cationic nanocomplexes
administered by CED [33]. In this anionic nanocomplexwe proposed that
the peptide provides a cationic bridge between anionic liposomes and
nucleic acids while also providing targeting properties via the receptor-
binding peptide ligand.
The peptide ligand YGLPHKF in peptide Y was identiﬁed by
biopanning a phage peptide library and closely resembles part of a
targeting protein expressed by the intracellular pathogen Legionella
pneumophila [31,34] although the identity of the receptor is unknown
[35]. However, we have demonstrated that this peptide mediates
targeted delivery of siRNA in cationic nanocomplexes to cells of neuro-
nal origin [34,36]. In this study we have adapted this formulation to
create anionic nanocomplexes by substituting cationic liposomes with
anionic liposomes and adjusting the ratio of peptide and liposome
components appropriately. In particular we have explored in vitro
the effects of PEGylation on the biophysical and transfection proper-
ties of the anionic RTNs. In vivo, we have compared anionic and
cationic PEGylated RTNs for dispersal and transfection in rat brain
administered by convection-enhanced delivery (CED), a method
that can achieve widespread dispersion of therapeutics from a single
administration [37–43].
2. Materials and methods
2.1. Materials
All lipids used in this study are shown in Supplementary Table 1.
1,2- dioleoyl-sn-glycero-3- phospho-(1′- rac-glycerol) (DOPG),
1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA),
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine
B sulfonyl) (DOPE-Rhodamine), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DPPE-PEG2000), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DOPE-PEG2000) and DOTMA/
DOPE (1:1 molar ratio) were purchased from Avanti Polar Lipids
(Alabaster, Alabama, USA). GdDOTA(GAC12)2 was provided by Dr
Botta (Alessandria, Italy) [44]. Peptide Y (K16GACYGLPHKFCG; net
charge +18), ligand YL (YGLPHKF; net charge +2) and ligand YSL
(YKHPGFL; net charge +2) were synthesized by ChinaPeptides
(Shanghai, China), while the non-targeting peptides PS (K16GACH
PPMSKLCG; net charge +18) and peptide K16 (KKKKKKKKKKKKKKKK;
net charge +16) were synthesized by Alta Biosciences (Birmingham,
UK). The plasmid pCI-Luc consists of the luciferase gene from pGL3
(Invitrogen, Paisley, UK) subcloned into pCI (Promega, Southampton,
UK). The plasmid pEGFP-N1 (4.7 kb) containing the gene GFP was ob-
tained from Clontech (Basingstoke, UK). The oligonucleotide primers
and standards for qRT-PCR were provided by qStandard (Middlesex,
UK) and were as follows: eGFP: forward primer 5′-CTTCAAGATCCGCC
ACAACAT-3′ and reverse primer 5′-GGTGCTCAGGTAGTGGTTGTC-3′;
Rpl13: forward primer 5′-CCCTACAGTTAGATACCACACCAA-3′ and re-
verse primer 5′-GATACCAGCCACCCTGAGC-3′; Beta actin: forward
primer 5′-ACGGTCAGGTCATCACTATCG-3′ and reverse primer 5′-AGCC
ACCAATCCACACAGA-3′; Sdha: forward primer 5′-TGGACCTTGTCGTC
TTTGG-3′ and reverse primer 5′-TTTGCCTTAATCGGAGGAAC-3′.
2.2. Liposome formulation
Lipids were dissolved in chloroform at 10 mg/mL then a lipid
ﬁlm was produced in a rotary evaporator by slowly evaporating thechloroform. Lipids were rehydrated with sterile, distilled water while
constantly rotated overnight, and then sonicated in a water bath to re-
duce their size. Anionic liposomes made were: DOPG:DOPE (LA) at 1:1
molar ratio; DOPG:DOPE:DPPE-PEG2000 (LAP1) at a molar ratio of
47.5:47.5:5 mol%, respectively; DOPG:DOPE:DOPE-PEG2000 (LAP2) at
a molar ratio of 47.5:47.5:5 mol%, respectively. An anionic liposome
labeled with gadolinium and rhodamine (LAPRG) was prepared with a
mixture of DOPG:DOPE:DOPE-PEG2000:DOPE-Rhodamine:GdDOTA
(GAC12)2 at a molar ratio of 39.5:39.5:5:1:15 mol%, respectively. A
cationic liposome labeled with gadolinium and rhodamine (LCPRG)
was also formulated consisting of DOTMA:DOPE:DOPE-PEG2000:
DOPE-Rhodamine:GdDOTA(GAC12)2 at a molar ratio of 39.5:39.5:
5:1:15 mol%, respectively. A = anionic, P = PEGylated, C = cationic,
R = rhodamine and G = gadolinium.
2.3. Nanoparticle formulation
Two methods of formulating anionic nanocomplexes were evaluat-
ed. In both, nanocomplexes were prepared in water at a range of
molar charge ratios of L to D while the peptide P to D molar charge
ratio was maintained constant at 3:1. Method 1 (L:D:P): DNA was ﬁrst
added to an anionic liposome (LA, LAP1 or LAP2) and incubated for
15 min at room temperature and then the peptide was added with
rapid mixing and incubated at room temperature for a further 20 min;
Method 2 (P:D:L): the peptide was added to the DNA and incubated
for 15 min at room temperature and then liposome was added with
rapid mixing and incubated at room temperature for a further 20 min.
Irrespective of the method of order of mixing, all molar charge ratios
in this study refer to L:P:D. Cationic formulations LPD and LCPRGPD
were prepared in the order L:P:D as described previously; ﬁrst, the pep-
tide was added to the liposome DOTMA/DOPE or LCPRG followed by ad-
dition of the DNA with rapid mixing and incubated for 30 min at room
temperature to allow for complex formation [30]. The nanocomplexes
prepared were termed LPD (liposome DOTMA/DOPE), LADP and PDLA
(liposome LA), PDLAP1 (liposome LAP1), PDLAP2 (liposome LAP2),
PDLAPRG (liposome LAPRG) and LCPRGPD (liposome LCPRG).
2.4. In vitro transfections
The murine neuroblastoma cell line Neuro-2A (ATCC, Teddington,
UK), and the rat neuroblastoma cell lines B104 (ICLC, Genova, Italy)
and B103 (AddexBio, San Diego, USA) were maintained in Dulbecco's
Modiﬁed Eagle Medium, 1% non-essential amino acids, 1 mM sodium
pyruvate and 10% FCS (Invitrogen, Paisley, UK). The human bronchial
epithelial cells 16HBE14o− were provided by D. Gruenert (San
Francisco, CA, USA) and were cultured in Eagle's Minimal Essential
Medium with HEPES modiﬁcation (Sigma-Aldrich, Poole, UK), 10% FCS
and 2 mM L-glutamine. All cells were maintained at 37 °C in a humidi-
ﬁed atmosphere in 5% carbon dioxide. Cells were seeded in 96-well
plates at 2 × 104 per well 24 h prior to transfection. Following removal
of growth medium, 200 μL of the complexes in OptiMEM containing
0.25 μg of plasmidDNAwere added to the cells in replicates of six. Plates
were centrifuged at 1500 rpm for 5 min (400 ×g) and incubated for 4 h
at 37 °C, then themediumwas replaced by the full growthmedium and
incubated for a further 24 h. Luciferase expression was then measured
in cell extracts with a luciferase assay (Promega, Southampton, UK) in
a FLUOstar Optima luminometer (BMG Labtech, Aylesbury, UK). The
amount of protein present in each cell lysate was determined with the
Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hemel Hemp-
stead, UK) in a FLUOstar Optima luminometer. Luciferase activity was
expressed as relative light units per milligram of protein (RLU/mg).
Each measurement was performed in groups of six and the mean
determined.
Neuro-2A cells were seeded in 96-well plates at 1.2 × 104 per well
24 h prior to transfection with 175 μL complete serum-containing
media. Twenty-four hours later, 25 μL of the complexes in OptiMEM
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cates of six. Plates were centrifuged at 1500 rpm for 5 min (400 ×g)
and incubated for 48 h at 37 °C. They were then ﬁrstly imaged (20×
magniﬁcation) using an Olympus IX70 ﬂuorescent microscope (Olym-
pus, Southend-on-Sea, UK) then prepared for ﬂow cytometry by
detaching cells from thewells with 50 μL Trypsin-EDTA (Sigma-Aldrich,
Poole, UK) and re-suspending them with 150 μL DPBS (Sigma-Aldrich,
Poole, UK). Cells were then acquired with a BD FACSArray ﬂow
cytometer (BD Biosciences, Oxford, UK) and analyzed with FlowJo
software v. 8.8.3 (Tree Star Inc., Ashland, Oregon, USA).
For competition experiments we modiﬁed a previously published
method [45]. Neuro-2A cells were seeded in 96-well plates at 1.2 × 104
per well 24 h prior to transfection. The cells were pre-incubated with
free ligands YL or YSL for 90 min prior to the addition of nanocomplexes
at a ﬁnal concentration of 100 μM. The media was then replaced with
200 μL of nanocomplexes per well containing 0.25 μg of GFP plasmid
DNA that also contained free ligands YL or YSL at a ﬁnal concentration
of 100 μM. Plates were centrifuged at 1500 rpm for 5 min (400 ×g) and
incubated for 4 h at 37 °C, then the medium was replaced by the full
growth medium without any ligands and incubated for a further 48 h.
They were then prepared for ﬂow cytometry analysis as above.
2.5. Particle size and charge measurements
Nanocomplexes were prepared as above and diluted with distilled
water to a ﬁnal volume of 1 mL and a concentration of 5 μg/mL DNA.
They were then analyzed for size and charge (ζ potential) using a
Malvern Nano ZS (Malvern, UK). The data were then processed by soft-
ware provided by the manufacturer, DTS version 5.03. All formulations
had a polydispersity index (PDI) of less than 0.3.
2.6. Turbidity assay
The turbidity of nanocomplex suspension in different serum concen-
trations (0–50% v/v) was determined from absorbance at 500 nm on a
FLUOstar Optima spectrophotometer with a corresponding amount
of serum alone as a reference [46]. Nanocomplexes were formed as
described above with 1 μg DNA in a volume of 200 μL, incubated at
37 °C and analyzed at regular time points over a 30 min period. Relative
turbidity was determined by dividing the sample absorbance by the
time zero value in water.
2.7. PicoGreen ﬂuorescence quenching experiments
Brieﬂy, 0.2 μg DNA was mixed with PicoGreen reagent (1:150)
(Invitrogen, Paisley, UK) at room temperature in TE buffer and the
DNA/PicoGreen mixture was then formulated into nanocomplexes
with anionic liposome and cationic peptide as described above. Fluores-
cence was analyzed using a ﬂuorescence plate reader, FLUOstar Optima
(BMG Labtech, Aylesbury, UK).
In nanocomplex dissociation assays, heparin sulfate (Sigma-Aldrich,
Poole, UK) was added to the PicoGreen-labeled nanocomplexes in a
range of concentrations (0.05–2 U/mL). In each experiment, naked
DNA stained with PicoGreen was used to normalize the PicoGreen
signal detected from the nanocomplexes.
2.8. Transmission electron microscopy (TEM)
Prior to use, 300-mesh copper grid coated with a Formvar/carbon
support ﬁlm (Agar Scientiﬁc, Essex, UK) were “glow discharged” in an
Emitech K350G system (Quorum Technologies, Essex, UK) for 15 s at
30 mA (positive polarity). The anionic nanocomplexes were prepared
in water as described above then applied onto a grid and after 5 s
dried by blotting with ﬁlter paper. The sample was then negatively
stained with 1% uranyl acetate for 2–3 s, before blotting with ﬁlter
paper and air-drying. Imaging was performed with a Philips CM120BioTwin Transmission Electron Microscope and operated at an acceler-
ating voltage of 120 kV. Images were captured using an AMT 5MP
digital TEM camera (Deben UK Limited, Bury St. Edmunds, Suffolk, UK).
2.9. Cell proliferation assay
Cell viability was assessed in 96-well plates using the CellTiter 96
Aqueous One Solution Cell Proliferation Assay (Promega, Southampton,
UK). Neuro-2A cells were seeded and transfected with anionic and
cationic nanocomplexes as above, then, after 24 h, the media were
substituted for growth media containing 20 μL of CellTiter 96 Aqueous
One Solution reagent. Finally, after incubation for 2 h, absorbance at
490 nm was measured on a FLUOstar Optima spectrophotometer
(BMG Labtech, Aylesbury, UK). Cell viability for each complex was
expressed as a percentage of the viability of control cells.
2.10. In vivo CED procedures
All in vivo studieswere performed in accordancewith the University
of Bristol animal care policies and with the authority of appropriate UK
Home Ofﬁce licenses. Adult male Wistar rats (Charles River, Margate,
UK, 225 to 275 g) were anesthetized and placed in a small animal
stereotaxic frame (Stoelting, Illinois, USA). All CED procedures were
performed using a custom-made catheter with an outer diameter of
0.22 mm and inner diameter of 0.15 mm, composed of fused silica
with a laser cut tip as described previously [43]. A total volume of 5 μL
of anionic and cationic PEGylated nanoparticles incorporating Gadolin-
ium and Rhodamine (190 ng eGFP/μL) for the striatum and 2.5 μL for
the corpus callosum was delivered at an infusion rate of 2.5 μL/min.
The Gadolinium dose delivered here is less than 4.5 μg, which is far
less than the50% lethal dose in rodentswhen theGadolinium is chelated
at 1–2 mg/kg or 100–200 mg/kg for the free ion [47]. Rats were culled
48 h following CED. For immunohistochemical analysis (IHC), animals
were transcardially perfusedwith 4% paraformaldehyde. Brainswere re-
moved and placed in 4% paraformaldehyde for 24 h, then cryoprotected
in 30% sucrose in order to be processed for histology. For qRT-PCR, brains
were explanted and rapidly frozen at−80 °C until required.
2.11. MRI
MRI measurements were performed on a 9.4 T VNMRS horizontal
bore scanner (Varian Inc. Palo Alto, CA) using a 59/26 Rapid quadrature
volume coil. Fixed rat brains were imaged using a T1-weighted gradient
echo 3D sequence (TR = 17 ms, TE = 4 ms, FA = 52o, 40 μm isotropic
resolution, Ave = 6). Distribution volumes were measured by
segmenting the hyperintensities caused by the gadolinium containing
nanoparticles using Amira (Visage Imaging Inc., San Diego, CA, USA).
2.12. Histological assessment and cell staining
Rat brains were cut into 35 μm thick coronal sections using a Leica
CM1850 cryostat (Leica Microsystems, Wetzlar, Germany) at−20 °C.
For ﬂuorescent immunohistochemistry, ﬁxed sections were mounted
on gelatine-subbed slides. Once dry, the sections were washed with
PBS for 5 min × 3. Sections were blocked in PBS plus 0.1% triton-x-
100 containing 10% normal donkey serum (Sigma-Aldrich, Poole, UK)
for 1 h at RT. They were then washed with 0.1% triton-x-100 in PBS
for 5 min. Following washing, sections were incubated in the following
primary antibodies: mouse anti-NeuN (1:300; Merck Millipore, MA,
USA), rabbit anti-GFP (1:200; Merck Millipore, MA, USA). The next
day, the primary antibody was removed and sections were washed
with 0.1% triton-x-100 in PBS for 5 min × 3. Sections were incubated
with donkey anti-Mouse Cy3 or donkey anti-rabbit Cy3 (1:300; Jackson
Laboratories, Sacramento, CA, USA) and DAPI (1:200 of 1 mg/mL;
Sigma-Aldrich, Poole, UK) at RT for 2 h in the dark and then washed
with PBS for 5 min × 3. Sections were mounted in Fluorsave™
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viewing. Images were captured using the Stereo Investigator platform
(MicroBrightField Bioscience, Williston, VT, USA) with a Leica DM5500
microscope (Leica Microsystems, Germany) and digital camera
(Microbrightﬁeld Bioscience, Williston, VT, USA). Some slides were vi-
sualized by confocal microscopy on a Carl Zeiss LSM710 laser scanning
microscope system (Jena, Germany) at a magniﬁcation of ×400.
2.13. qRT-PCR
Rat brains (n = 3 per formulation) were collected in RNAlater
(Invitrogen, Paisley, UK) and total RNA was extracted from rat brain
using the RNeasy kit according to the manufacturer's instructions
(Qiagen, Crawley, UK). RNA was checked for integrity using the Agilent
2100 Bioanalyzer (Wokingham, UK). All RNA samples had a RNA integ-
rity number (RIN) of more than 9 indicating high quality RNA. Prior
to reverse transcription, each sample underwent DNase treatment
(Invitrogen, Paisley, UK) to eliminate any potential genomic DNA
contamination. First-strand DNA was synthesized from 1 μg of DNase-
treated RNA, using random hexamers and Superscript II reverse
transcriptase (Invitrogen, Paisley, UK) in a 1 h reaction at 37 °C. eGFP,
rat Succinate dehydrogenase complex subunit A (Sdha), rat Ribosomal
protein L13 (Rpl13) and rat beta actin mRNA levels were then quanti-
ﬁed by SYBR Green qRT-PCR using a an ABI PRISM 7000 Sequence
Detection System (Applied Biosystems, Warrington, UK). The qRT-PCR
assay conditions were: stage 1, 50 °C for 2 min; stage 2, 95 °C for
10 min; stage 3, 95 °C for 15 s, then 60 °C for 1 min and repeated 40
times. Ampliﬁcation efﬁciency was 101% (eGFP), 102% (Rpl13), 102%
(beta actin) and 103% (Sdha). Copy numbers for eGFP and the three
housekeeping genes were derived from standard curves constructed
of puriﬁed PCR products generated for each speciﬁc primer pair ranging
from 107 to 101 copies for eGFP, Rpl13, beta actin and Sdha. Copy num-
bers of eGFP were normalized against the geometric mean of Rpl13 and
beta actin, which were the most stable genes.
2.14. Statistical analysis
Data presented in this study are expressed as the mean ± standard
deviation andwere analyzed using a two-tailed, unpaired Student t-test
or one-way ANOVA and Bonferroni post-hoc analysis where applicable.
Probability values p b 0.05 were marked with *, p b 0.01 were marked
with ** and p b 0.001 were marked with ***.
3. Results
3.1. Development and characterization of anionic nanoparticles
LDP (Method 1) or PDL (Method 2) nanocomplexeswere formulated
at anionic liposome:DNA (L:D) molar charge ratios from 5:1 to 1:1. Zeta
potential analysis showed that LDP and PDL nanocomplexes became
strongly anionic when the L:D molar charge ratio was 3.5:1 or greater
with no signiﬁcant size or charge differences (Fig. 1A and B).
PicoGreen ﬂuorescence assays (Fig. 1S-A) showed that PDL formula-
tions quenched ﬂuorescence better than LDP formulations at the 5:3:1
molar charge ratio (37% quenching for LDP vs. 61% for PDL; p b 0.01)
but there was no difference at the 4:3:1 ratio. Luciferase transfection
efﬁciency comparisons in B104 and 16HBE14o− cells (Fig. 1S-B and C,
respectively) showed that the PDL order of mixing was substantially
better than LDP at allmolar charge ratios. Therefore, based onpackaging
and transfection efﬁciencies, the PDLmethod of mixingwas used there-
after for all anionic nanocomplexes.
Anionic liposomes (DOPG/DOPE)were then preparedwith PEGylated
lipids incorporated at 5% molar ratios and these liposomes were used to
prepare the anionic PEGylated nanocomplexes PDLAP1, containing the
DPPE-PEG2000 liposome, and PDLAP2 containing DOPE-PEG2000. The
PEGylated nanocomplexes were both prepared at molar charge ratios of5:3:1 and 4:3:1 and were conﬁrmed to be anionic (Fig. 1C). PDLAP2
nanocomplexes were bigger than both the non-PEGylated PDLA and
cationic LPD (Fig. 1C) while they were also less anionic (e.g.−36 mV
for PDLAP2 compared to −49 mV for PDLA). The stability of nano-
complexes in 50% mouse serum was assessed where the turbidity of
both PEGylated and non-PEGylated, anionic PDL nanocomplexes was
less than half that of the cationic LPD formulation (Fig. 1D).
The ability of anionic nanocomplexes to package DNA efﬁciently and
to dissociate following heparin challenge in order to release intact DNA
was then assessed. PicoGreen-labeled DNAwas formulated into cationic
LPD and anionic PDL, PEGylated and non-PEGylated nanocomplexes at
4:3:1 molar charge ratios. Packaging was inferred from quenching of
ﬂuorescence compared to free DNA as 100%. Non-PEGylated PDLA at
65% quenching, packaged less well than cationic LPD at 85% quenching,
although PEGylation improved packaging in anionic formulations with
both PDLAP1 and PDLAP2 also quenching DNA ﬂuorescence by 80%
(Fig. 2). On the other hand, PDLA was the least sensitive formulation to
heparin with ﬂuorescence increasing only to 48.8%, even in the presence
of 2 U/mLheparin, whereas cationic LPD only required 0.4 U/mL heparin
to achieve 50% dissociation. PEGylation of anionic nanocomplexes great-
ly increased their sensitivity to heparin, achieving 50% dissociation at
0.14 U/mL heparin for PDLAP1 and 0.32 U/mL of heparin for PDLAP2
nanocomplexes (Fig. 2).
Anionic PDL nanoparticle formulations were further characterized
by negative staining transmission electron microscopy (TEM) to deter-
mine shape and morphology. Most nanocomplexes were spheres but
with some rods, while PDLAP2 also showed some ‘doughnut’ structures
(Fig. 3). The majority of the spherical particles for each formulation
were in the range determined by particle size analysis with no obvious
differences between formulations.
3.2. Enhanced targeted cell transfection efﬁciency and viability of
anionic PDLs
Anionic PDL formulationswere then compared with cationic formu-
lations for cytotoxicity and targeted transfection efﬁciency in three neu-
roblastoma cell lines, mouse Neuro-2a and rat B103 and B104. In MTS
toxicity assays of transfected Neuro-2A cells (Fig. 4A) all three anionic
formulations were less toxic than cationic LPD (p b 0.01). In Neuro-2A
cells (Fig. 4B), both PEGylated anionic nanocomplexes were more efﬁ-
cient transfection agents than the non-PEGylated PDLA (p b 0.001)
with PDLAP2 showing optimal transfection efﬁciency and receptor spec-
iﬁcity. The targeted transfection efﬁciency of anionic nanocomplexes
with the targeting peptide, peptide Y, was 17.6-fold, 80.3-fold and
75-fold higher than those with K16 and 5-fold, 2.6-fold and 11.7-fold
higher than thosewith peptide PS for PDLA, PDLAP1 and PDLAP2, respec-
tively, while cationic LPD formulations with peptide Y were enhanced
only 1.8-fold compared to K16 and 1.3-fold compared to PS, highlighting
the greater targeting speciﬁcity of the anionic formulations. The trans-
fection efﬁciency of PDLAP2 containing peptide Y was signiﬁcantly
better than PDLAP1 (p b 0.01) and this was also the more stable formu-
lation in the heparin dissociation studies.
The same trends were observed in B103 cells (Fig. 4C) and B104 cells
(Fig. 4D) where the targeted transfection efﬁciency and speciﬁcity of
anionic PDLAP2 was again signiﬁcantly better than that of cationic LPD
(p b 0.001). PDLAP2 with peptide Y was about two-fold better than
the scrambled PS formulation (p b 0.05) although both anionic and
cationic formulations were signiﬁcantly improved over non-targeting
K16 formulations. In B104 cells (Fig. 4D) the transfection efﬁciency of pep-
tide Y-targeted PDLAP2 formulationwasmore than thirty-fold better than
that that of the scrambled PS and non-targeting K16 formulations and al-
most 2-fold better than the peptide Y-targeted cationic LPD formulation.
The transfection efﬁciencies of anionic PEGylated formulations
were then compared with the plasmid expressing enhanced green ﬂuo-
rescent protein (GFP) in Neuro-2A cells. Flow cytometry analysis showed
that, in the presence of 10% serum, peptide Y-targeted PDLAP2 transfected
Fig. 1. Development of anionic nanoparticles and biophysical characterization. (A) Anionic LADP nanoparticles were prepared with Method 1 of mixing (L:D:P; liposome with DNA were
mixed ﬁrst followed by mixing with peptide Y) at different molar charge ratios and their size and charge wasmeasured by dynamic light scattering. All formulations had a polydispersity
index (PDI) of less than 0.2. (B) Anionic PDLA nanoparticleswere preparedwithMethod 2 ofmixing (P:D:L; peptide Ywith DNAweremixedﬁrst followed bymixingwith the liposome) at
differentmolar charge ratios and their size and chargewasmeasured by dynamic light scattering. All formulations had a PDI of less than 0.2. (C) Anionic PEGylated PDLAP1 and PDLAP2 and
non-PEGylated PDLA nanoparticles madewithMethod 2 ofmixingwere prepared at different molar charge ratios and their size and chargewasmeasured by dynamic light scattering and
compared with that of cationic LPD. All formulations had a PDI of less than 0.3. (D) The effect of 50% serum concentration on the relative turbidity of cationic and anionic nanocomplexes
over a 30 min incubation period. Cationic LPD nanocomplexes were made at a 1:4:1 weight ratio, whereas the anionic nanocomplexes (non-PEGylated PDLA and PEGylated PDLAP1 and
PDLAP2) were all made at a 4:3:1 molar charge ratio. Peptide Y was used for all formulations.
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maximum of 22% cells (p b 0.001; Fig. 4E). In addition, targeted transfec-
tion speciﬁcitywas againmore evidentwith PDLAP2 than LPDwhen com-
paring with K16 and PS-containing formulations (Fig. 4E). The speciﬁcityFig. 2. Heparin dissociation studies to examine packaging properties of the nanocomplexes.
The dissociation properties of anionic nanocomplexes PDLA, PDLAP1 and PDLAP2 at 4:3:1
molar charge ratios and cationic nanocomplex LPD were investigated. PicoGreen ﬂuores-
cence of complexes, after incubation with heparin (0–2 U/mL), was expressed as a percent-
age of RFU relative to free DNA. Peptide Y was used for all formulations.of gene delivery by peptide Y was further demonstrated in competition
experiments using excess free ligand YL (i.e. only the targeting motif of
peptide Y) or excess free scrambled ligand YSL (i.e. only a scrambled
motif). GFP transfection following peptide Y-mediated gene delivery
was 44-fold and8-fold reduced (p b 0.001 for both)when the gene trans-
fer was performed in the presence of free ligand YL for PDLAP2 and LPD
nanocomplexes, respectively, whereas no signiﬁcant difference was ob-
served in the presence of free ligand YSL (Fig. 4F). There was no effect
of ligand YL or ligand YSL on peptide PS-mediated gene transfer. Re-
duction in reporter gene transfection was also observed when the
competition experiments were performed for luciferase expression
in the presence of YL ligand (approximately 12-fold and 4-fold for
PDLAP2 and LPD, respectively; p b 0.001 for both), whereas no effect
was observed in the presence of YSL (Fig. 2S). Fluorescent microsco-
py images also provided evidence of the high transfection efﬁciency
of PDLAP2 anionic nanoparticles (Fig. 5).
3.3. In vivo administration by CED of anionic PDLs demonstrated signiﬁcant
brain distribution and transgene expression
Targeted, anionic and cationic, PEGylated formulations were pre-
pared with liposomes labeled with ﬂuorescent rhodamine and gadolin-
ium, anMRI contrast agent (Table 1). Formulations containingGFPwere
administered to rat brains by CED into the corpus callosum and the
Fig. 3.Electronmicroscopyof nanocomplexes. Negative staining transmission electronmi-
croscopy was used to visualize (A) PDLA, (B) PDLAP1 and (C) PDLAP2 nanoparticles. Scale
bar = 100 nm for (A and C) and 500 nm for (B). Peptide Y was used for all formulations.
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(Fig. 6A) and 3D reconstructions (Fig. 6B) showed that in the corpus
callosum infusions the distribution volumes of anionic Ani PDLAPRG for-
mulations was increased approximately 2-fold (p b 0.05) and 22-fold
(p b 0.001) compared to the cationic formulations Cat PDLAPRG
and Cat LCPRGPD, respectively (Fig. 6C). Distribution volumes for all for-
mulations were lower in the striatum than the corpus callosum due to
the denser nature of the tissue but an increase in distribution of anionic
Ani PDLAPRG nanocomplexes compared to Cat PDLAPRG (5-fold; p N 0.05)
and Cat LCPRGPD formulations (25-fold; p b 0.01) was observed in the
striatum infusions.
Histological analysis of brain sections (Figs. 6D and 3S) also sug-
gested better distribution of the anionic rather than cationic nanoparti-
cles but was not quantiﬁed. Rat brain sections (Fig. 6E) showed that the
rhodamine-labeled nanoparticles expressed GFP within the striatum as
well as the cortex, where transfection occurred due to nanoparticles
reﬂuxed up the catheter tract on withdrawal of the cannula. Conﬁrma-
tion of GFP transgene expressionwas achieved by quantitative real time
polymerase chain reaction (qRT-PCR) using samples of total RNA
(Fig. 6F) from two regions of the brain (corpus callosum and striatum).
Highest expression levels were achieved by cationic formulation
Cat PDLAP2 especially in the striatum, followed by the anionic formula-
tion Ani PDLAP2, with no statistical differences among the groups.
4. Discussion
Many of the limitations of synthetic nanoparticle formulations
in vivo, such as poor tissue speciﬁcity, toxicity and rapid clearance
from the circulation, relate to their cationic surface charges. Stealth
coatings such as PEGylation overcome some of these problems but
often lead to reduced transfection efﬁciency [11]. For these reasons,
neutral and anionic nanocomplex formulations have gained traction in
the ﬁeld in recent years although the level of research remains far
below that of cationic formulations. One of the ﬁrst such approaches in-
volved a formulation of anionic liposomes and cationic protamine with
DNA, targeted to tumor cells by folate [48] and various derivatives of
this formulation have been developed in recent years [21,22,49–51].
Other effective approaches of preparing anionic nanocomplexes involve
the use of electrostatic, anionic coating agents such as hyaluronan,
polyglutamate and chondroitin sulfate applied to a cationic core nano-
particle [52–55]. Such approaches have enabled the production of high-
ly anionic nanoparticles that display comparable levels of transfection to
cationic formulations but with advantages of greater speciﬁcity and
lower cytotoxicity. Anionic DNA-delivery formulations have shown
promising evidence of improved efﬁcacy, biodistribution and reduced
toxicity compared to cationic formulations when administered system-
ically for targeting of tumors [23,48,53,56]. Anionic formulations have
also been described for siRNA transfection with similarly promising re-
sults [16,17,24,57,58]. There is therefore a need for more research into
the potential of anionic formulations to optimize their design, formula-
tion and applications.
We are developing a platform of anionic, targeted nanocomplex
formulations comprising a mixture of peptide ligands and anionic
liposomes that self-assemble into anionic nanocomplexes with DNA at
optimized ratios of components and order of mixing. Our ﬁrst such
formulation displayed far superior distribution in rat brain than homol-
ogous cationic nanocomplexes following CED administration [33]. Here
we have focused on developing this formulation further, investigating
the effects of PEGylation and an alternative targeting moiety, peptide
Y. We relate the biophysical properties of these novel nanocomplexes
to their transfection efﬁciencies in vitro and in vivo in rat brain, as well
as brain distribution by MRI.
Anionic nanocomplex formulation protocols were ﬁrst optimized in
terms of method of mixing andmolar charge ratios, then structural and
functional studies were performed to compare the PEGylated formula-
tions with non-PEGylated anionic and cationic formulations. The
Fig. 4. In vitro transfectionswith anionic nanocomplexes show the targeting effect of peptide Y and lack of cytotoxicity. (A) Viability of Neuro-2A cells following transfection for 24 hwith
PDLA, PDLAP1, PDLAP2 and LPD. Cationic nanocomplexes were made at a weight ratio of 1:4:1 (L:P:D) and the anionic nanocomplexes at a molar charge ratio of 4:3:1 (L:P:D). Viability
values were normalized to the untransfected control cells. Anionic formulations are shown in gray and cationic formulations in white. Peptide Y was used for all formulations.
(B) Nanocomplexes LPD, PDLA, PDLAP1 and PDLAP2 were used in luciferase transfections in Neuro-2A cells, (C) LPD and PDLAP2 in B103 cells and (D) LPD and PDLAP2 in B104 cells. All
were made with 3 different peptides: peptide Y, scrambled peptide PS and peptide K16. Cationic nanocomplexes were made at 1:4:1 weight ratio, whereas all anionic were made at
4:3:1 molar charge ratio. (E) Cationic LPD nanocomplexes (weight ratio 1:4:1) and anionic PDLAP2 nanocomplexes at 4:3:1 molar charge ratio and made with three different peptides
(peptide Y, scrambled peptide PS and peptide K16) were used in GFP transfections in Neuro-2A cells in serum-containing media. 48 h later the cells were trypsinized and analyzed by
ﬂow cytometry for GFP expression. (F) Cationic LPD nanocomplexes (weight ratio 1:4:1) and anionic PDLAP2 nanocomplexes at 4:3:1molar charge ratiomadewith two different peptides
(peptide Y and scrambled peptide PS)were used in GFP transfections in Neuro-2A cells. Competitive inhibition of peptide Y-mediated gene deliverywas performed either in the presence
or in the absence of free ligandYL or free scrambled ligandYSL and serum. The cellswere pre-incubatedwith the free ligands at a concentration of 100 μMfor 90minprior to the addition of
nanocomplexes. The graph shows %GFP gene expression relative to LPD (Y) for the cationic nanoparticles and relative to PDLAP2 (Y) for the anionic nanoparticles. Each column represents
themean ± SD from six wells. All transfections were performed in groups of six andmean values were calculated. Asterisks indicate comparisons of speciﬁc formulations with statistical
signiﬁcance (*, p b 0.05; **, p b 0.01; ***, p b 0.001).
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Fig. 5. GFP transfection efﬁciency of the PEGylated anionic nanoparticles is higher com-
pared with a cationic counterpart. Two formulations, one cationic (LPD) and one anionic
(PDLAP2), were used to transfect Neuro-2A cells in serum-containing media. GFP expres-
sion was observed by epiﬂuorescence microscopy 48 h later (representative cells are
shown in phase-contrast and transfected cells appear green; 10× magniﬁcation). Peptide
Y was used for all formulations. UNTR = untransfected cells.
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PEGylated PDLA. The anionic PEGylated nanoparticleswere slightly larg-
er in diameter than non-PEGylated anionic formulations, while their
charge was less anionic due probably to PEG shielding. TEM images of
anionic nanoparticles showed that there were no signiﬁcant differences
inmorphology between the different PEGylated and non-PEGylated an-
ionic formulations and cationic LPD formulations reported previously
[34].
DNA packaging was signiﬁcantly less efﬁcient in anionic PDLA
formulations than in cationic LPD although PEGylation improved it to
80% from 65% in the non-PEGylated anionic formulation, which
matched that of the cationic LPD formulation with approximately 85%
efﬁciency. We then tested nanoparticle stability using mouse serum at
50% concentration (v/v) which approximates in vivo conditions [46].
PEGylated and non-PEGylated PDLA formulations were far more stable
in serum than cationic nanocomplexes which aggregated due to their
interactions with anionic serum proteins [59]. Aggregation of cationic
liposomes leads to reduced bioavailability, increased toxicity, reducedTable 1
Composition of liposomes and associated size and zeta potential of nanocomplexes as measu
liposomes is shown in parentheses. Cat LCPRGPD was made at 1:4:1 weight ratio, Cat PDLAPRG
ratio. Peptide Y was used for all formulations.
Liposome Lipid 1 (mol %) Lipid 2 (mol %) Lipid 3 (mol %) Lipid 4 (mol %)
LCPRG DOTMA (39.5) DOPE (39.5) DOPE-PEG2000 (5) GdDOTA (GAC12
LAPRG DOPG (39.5) DOPE (39.5) DOPE-PEG2000 (5) GdDOTA (GAC12
LAPRG DOPG (39.5) DOPE (39.5) DOPE-PEG2000 (5) GdDOTA (GAC12binding to cells and clearance in vivo of cationic nanoparticles by the re-
ticuloendothelial system (RES) [46,60] and so we anticipate improved
properties for anionic nanoparticles administered systemically.
While extracellular stability is an essential requirement for an
efﬁcient nucleic acid delivery formulation, effective transfection is also
inﬂuenced by the ease of release of the cargo within the cell [36]. The
cationic LPD formulation dissociatedmore easily and to a greater extent
after treatment with heparin than PDLA. However, PEGylation greatly
enhanced the dissociation potential of anionic nanocomplexes particu-
larly for PDLAP1. The PEGylated lipidmoiety in PDLAP1 is a C16 saturated
acyl chainwhile in PDLAP2 it is a C18 unsaturated acyl chain. Longer acyl
chains (C18 vs. C16) strengthen membrane cohesion of liposomes and
this may explain the greater stability of PDLAP2 [61]. In addition, PEG-
lipids with the shortest acyl chain, provided the least liposome protec-
tionwith rapid elimination of the liposomes from the circulationwithin
1 h after liposome injection [62]. The different sensitivities of PEGylated
and non-PEGylated anionic nanocomplexes to heparin, may be ex-
plained by the greater anionic charge of the latter increasing resistance
to dissociation. Toxicity assays showed that there was no difference be-
tween the PEGylated and non-PEGylated anionic formulations although
therewas someevidence of toxicity for the cationic formulations consis-
tent with previous studies comparing anionic and cationic formulations
[21,22,24].
We then compared the transfection efﬁciencies of the anionic
formulations in different cell lines using different peptides, targeting
(peptide Y) and non-targeting (peptides PS and K16). Comparing
peptide Y-targeted nanocomplexes, PDLAP2 formulations produced
signiﬁcantly better luciferase transfection efﬁciencies than PDLAP1 and
similar to the efﬁciency of a cationic LPD formulation, while non-
PEGylated PDLA was far less efﬁcient. GFP transfections also showed
the greater transfection efﬁciency of PDLAP2 when compared to
PDLAP1 and cationic LPD formulations.
Peptide Y-targeted anionic formulations produced much better
transfection efﬁciencies than their non-targeted counterparts contain-
ing peptide PS or K16 in all cell lines examined, suggesting receptor-
speciﬁc transfection. The receptor for peptide Y is unknown and so to
evaluate receptor-mediated transfection speciﬁcity, cells were incubat-
ed with the competing peptide ligand, YL, before transfectingwith pep-
tide Y-containing nanocomplexes. This led to reduced transfection of
both peptide Y-targeted anionic and cationic nanocomplexes,
although the degree of inhibition of transfection was much greater
with the anionic formulation. The scrambled control peptide, YSL, had
no effect on transfection in targeted formulations, while transfections
of cells containing non-targeting peptide PS were not affected by either
YL or YSL. These studies support the hypothesis that anionic nano-
complexes transfect by receptor-speciﬁc pathways, while cationics
transfect by charge-mediated non-speciﬁc routes, which can be
enhanced by a targeting peptide ligand.
In relating differences in transfection efﬁciency to biophysical prop-
erties, PDLA, the least effective transfection agent, possessed the highest
anionic charge and was the least efﬁcient formulation for both DNA
packaging and release, although its high anionic charge was associated
with signiﬁcantly higher speciﬁcity for ligand-mediated transfection
than that of cationic LPD. The high anionic surface charge would reduce
cell surface interactions and endocytosis and this, combined with the
poor DNA release kinetics help to explain the poor transfectionred by dynamic light scattering. The molar ratio of each lipid that is used to make the 3
was made at 3:3:1 molar charge ratio and Ani PDLAPRG was made at 4:3:1 molar charge
Lipid 5 (mol %) LPD/PDL Size (nm) ζ potential (mV)
)2 (15) DOPE-Rhodamine (1) Cat LCPRGPD 186.0 (± 0.1) +57.0 (±0.8)
)2 (15) DOPE-Rhodamine (1) Cat PDLAPRG 149.8 (±2.1) +16.9 (±0.1)
)2 (15) DOPE-Rhodamine (1) Ani PDLAPRG 160.5 (±2.7) −37.9 (±5.3)
Fig. 6. In vivo distribution assessment of charged PEGylated nanoparticles into the striatum and corpus callosum after CED byMRI and histology and reporter gene delivery assessment by
qRT-PCR. (A) Optimized 3D T1-weighted gradient echo scans were performed to allow visualization of the gadolinium in the nanoparticles (representative scans from a rat that received
Ani PDLAPRG nanoparticles), and these data (B) were reconstructed as 3D datasets to allow volumetric distribution analyses after CED in the striatum (red) and corpus callosum (blue)
between cationic PEGylated nanoparticles Cat LCPRGPD (left; 1:4:1 weight ratio) and Cat PDLAPRG (right; 3:3:1 molar charge ratio) and anionic PEGylated nanoparticles Ani PDLAPRG
(bottom; 4:3:1molar charge ratio). (C) Distribution of the anionic and cationic PEGylatednanoparticles following infusions in the striatumand corpus callosumat 48h post administration
wasmeasured. Values are themeans of 3 animals ± standarddeviation (*, p b 0.05; **, p b 0.01; ***, p b 0.001). (D)Histological assessment in the striatumof (a–c) cationic PEGylatedCat
LCPRGPD nanoparticles, (d–f) Cat PDLAPRG nanoparticles, (g–i) anionic Ani PDLAPRG nanoparticles. (a, d, g) refer to rhodamine spread, (b, e, h) to GFP expression, (c, f,i ) to the corresponding
merged imageswhich show the cellular nature of the striatum byDAPI staining. (E) Cat PDLAPRG nanoparticles have shown clear distribution, with several neuronal speciﬁc cells detected
in the striatum. (a) DAPI stained cells, (b) GFP transfection, (c) NeuN antibody staining and (d) merged panel b and c. Scale bar = 100 μm; (e) confocal image from the cortex, whereby
reﬂux has allowed visualization of several GFP positive cells following administration of Ani PDLAPRG nanoparticles. Scale bar = 20 μm. (F) Functional delivery of the eGFP plasmid by the
cationic (Cat PDLAP2 at 3:3:1molar charge ratio) and anionic (Ani PDLAP2 at 4:3:1molar charge ratio) PEGylated nanoparticleswas also assessed byqRT-PCR. These two formulationswere
made without imaging markers. Values represent the mean of the mRNA copies of 3 animals per group ± standard deviation. Peptide Y was used for all formulations. CC = corpus
callosum, St = striatum.
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ciency of PEGylated anionic formulationswas associatedwith improved
dynamic properties of the nanocomplexes in that they both packaged
and released DNAmore effectively than the non-PEGylated formulation
and had lower anionic surface charge. In fact the optimal PEGylated for-
mulation PDLAP2 was a better transfection agent than even the cationic
LPD, displaying amuchhigher degree of receptor-mediated transfection
than cationic formulations. Of the two PEGylated formulations PDLAP2
was slightly more stable to heparin-mediated dissociation than
PDLAP1 but otherwise presented with similar biophysical properties of
size, charge and morphology. Thus PDLAP2 may better retain its struc-
tural integrity during the transfection process in the anionic environ-
ment of the cell surface while retaining greater dynamic properties for
DNA release within the cell, and hence achieve the greater transfection
efﬁciencies observed.
We then investigated an in vivo application involving direct injec-
tion of nanoparticles to the brain by CED where anionic formulations
offer the promise, of more widespread dispersal of nanoparticles
from a single administration as they are less likely to adhere to
cells non-speciﬁcally than similarly sized cationic nanoparticles
[33,43], while other studies suggested that surface modiﬁcation by
PEGylation further enhanced distribution of anionic [63] but not of
cationic nanoparticles [56,63]. In this study, nanocomplex formula-
tions were labeled with gadolinium and rhodamine to enable detec-
tion by MRI and ﬂuorescence microscopy, respectively [33].
Formulations compared for dispersal within the brain and transfec-
tion included, i) an anionic PDLAP2-based formulation, Ani PDLAPRG,
ii) a cationic formulation, Cat PDLAPRG, containing the same anionic
liposome as PDLAP2 but formulated with a lower amount of the an-
ionic liposome (DOPG/DOPE) to make cationic nanocomplexes, and
iii) a second cationic nanocomplex, Cat LCPRGPD, prepared with cat-
ionic liposomes. The distribution of the anionic formulation by MRI
was greater than either cationic formulation in both striatum and
corpus callosum. The difference in distribution between the Cat
LCPRGPD and Cat PDLAPRG, may be attributed to the higher positive
charge (+57.0 and +16.9 mV, respectively) (Table 1) leading to
an increase in non-speciﬁc binding close to the cannula tip [63].
Distribution for all formulations was greater in the corpus callosum
infusions due to the more compact nature of the striatum and the
consequent importance of size limitations on distribution. The qRT-
PCR analysis conﬁrmed that GFP transgene expression was achieved
in two regions of the brain (corpus callosum and striatum). All for-
mulations achieved transgene expression in both brain areas with
no statistical differences among the different groups. The higher
local concentration of the cationic formulation may provide an ad-
vantage for transfection near the injection site compared to the an-
ionic formulations, which are better dispersed but more diluted,
reducing their local transfection efﬁciency. Future studies will be
required to investigate optimal dosage for anionic formulations.
The potential for efﬁcient, targeted gene expression from anionic
nanocomplexes combined with their improved distribution by
CED suggests their utility for delivery of therapeutic genes to the
brain.
5. Conclusions
In this study we describe a novel, multifunctional, anionic nano-
complex and demonstrated that optimized PEGylation strategies
enhanced transfection efﬁciency and receptor-targeted speciﬁcity,
possibly by lowering repulsion forces from the anionic moieties on
the cell surfaces. This contrasts with cationic synthetic nanocomplex
formulations where PEGylation typically reduces transfection efﬁ-
ciency. Distribution of gadolinium-labeled nanocomplex formula-
tions in brain, administered by direct delivery, was improved in
anionic formulations with levels of transfection equivalent to cation-
ic formulations, demonstrating the potential for theranostic deliveryof genes and contrast agents to allow monitoring of biodistribution
by MRI.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2013.11.014.
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